DEF 14A

Company

Lyra Therapeutics, Inc.

Filed

April 4, 2025

Period of Report

May 14, 2025

Accession Number

0001193125-25-072918

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →